MENAT Butterfly Needles Market Developments and Forecast by 2028

The MENAT butterfly needles market is projected to reach US$ 12,073.4 thousand by 2028 from US$ 7,446.4 thousand in 2021. The market is estimated to grow at a CAGR of 7.2% during 2022–2028.

A butterfly needles, also called a winged infusion set or a scalp vein set, is used to access a vein to draw blood or give medications. The advantages of butterfly needles over straight needle are that it allows for more precise placement, particularly in hard-to-access veins. The MENAT butterfly needles market is majorly driven by the surging prevalence of chronic disease and rising cases of genetic blood disorders. However, the risk associated with butterfly needles tick injuries is hampering the MENAT butterfly needles market growth.

MENAT Butterfly Needles Market -

MENAT Butterfly Needles Market: Strategic Insights

Lucrative Country in MENAT Butterfly Needles Market

Market Insights - MENAT Butterfly Needles Market

Rising Cases of Genetic Blood Disorders

According to the Centre for Arab Genomic Studies based in the UAE, there are 906 genetic disorders endemic to Arab states. These include sickle cell disease (SCD), thalassemia, Tourette's syndrome, Wilson's disease, Charcot-Marie-Tooth disease, mitochondrial encephalomyopathies, hemoglobinopathy, and Niemann-Pick disease. According to a research article published in the Middle East Fertility Society Journal in 2021, the prevalence rate of G6PD deficiency among Egyptians is 1%, while 11.55% among Iranians. ~43.3% of adult patients in the Middle East are diagnosed with thalassemia. The prevalence of SCD in all Middle Eastern countries is approximately 0.04–2.1%. As per the research article published in Nature Journal in 2021, the prevalence rate of SCD is highest in Sub-Saharan Africa, where up to 45% of people carry the disease; Saudi Arabia's carrier rate is 27%; and in Lebanon, it is 2.1%.

Butterfly needles may have greater advantages for people with genetic blood disorders as the treatment includes frequent medication and blood transfusions.

MENAT, Application-Based Insights

Based on application, the MENAT butterfly needles market is segmented into blood collection, blood transfusion, venipuncture, IV rehydration, and delivery of medications. The blood collection segment held the largest share of the market in 2021. However, the IV rehydration segment is anticipated to register a CAGR of 8.1% in the market during the forecast period. Butterfly needles or winged infusion sets are uniquely designed devices used for blood collection. When the butterfly needles is inserted into a vein, a small amount of blood will enter the first section of the tube. A butterfly needles may be used by phlebotomists when collecting numerous tubes since this method makes changing tubes easier. Butterfly needles are less likely to cause blood breakdown than IV catheters, which is driving their demand for blood collection. They may also offer more advantages to patients with bleeding disorders such as hemophilia or von Willebrand's disease. According to an article published by Arab News, in December 2021, more than 10 blood donations have been donated per 1,000 population each year (more than 1%) in GCC countries. Dubai Blood Donation Centre received more than 53,000 units in 2019, which represents approximately half of all blood collected in the UAE. Dubai Health Authority and Dubai Holdings have partnered to conduct several initiatives throughout the year. Moreover, Terumo Corporation offers Surshield Safety Winged Blood Collection Sets which readily conform to the body with the help of soft, flexible interlocking wings. With a slight angle between the needle and the wings, there is less risk of vessel damage or occlusion, and the coil-resistant tubing reduces recoil.

MENAT Butterfly Needles Market, by Application – 2021 and 2028

MENAT Butterfly Needles Market, by End User-Based Insights

Based on end user, the MENAT butterfly needles market is segmented into hospitals, clinics, blood banks, and others. The hospitals segment held the largest share of the market in 2021 as the hospitals provide healthcare facilities through specialized scientific equipment. The increasing prevalence of chronic diseases such as cardiovascular disease, cancers, and bleeding disorders in MENAT is fueling the demand for butterfly needless in hospitals. According to World Heart Federation, more than one-third of all deaths in the Middle East and North Africa region are caused by cardiovascular disease (CVD), which kills 1.4 million people each year. Further, CVD is the leading cause of death in MENAT. According to the Centre for Agriculture and Bioscience International (CABI), cancer is already one of the most common causes of death in MENA and it is predicted that the number of new cases will nearly double by 2030. Further, rise in chemotherapy and increase in geriatric population in the MENA region are driving the MENAT butterfly needles market.

Product launches and approvals are commonly adopted strategies by companies to expand their footprints and product portfolios to dominate the butterfly needles market share. Moreover, the market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name in MENAT. The butterfly needles market share is anticipated to flourish with the development of new innovative products by market players.

Company Profiles

• Braun Melsungen AG
• Becton, Dickinson and Company
• Nipro Corporation
• Cardinal Health, Inc
• Medline Industries, Inc.
• Terumo Corporation
• Kawasumi Laboratories, Inc
• IUC Medical

MENAT Butterfly Needles Report Scope